Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

16.0%

2287 terminated/withdrawn out of 14337 trials

Success Rate

79.1%

-7.4% vs industry average

Late-Stage Pipeline

8%

1127 trials in Phase 3/4

Results Transparency

51%

4428 of 8662 completed trials have results

Key Signals

1405 recruiting4428 with results1679 terminated608 withdrawn

Enrollment Performance

Analytics

Phase 2
4937(39.6%)
Phase 1
3624(29.0%)
N/A
2551(20.4%)
Phase 3
1054(8.4%)
Early Phase 1
242(1.9%)
Phase 4
73(0.6%)
12481Total
Phase 2(4937)
Phase 1(3624)
N/A(2551)
Phase 3(1054)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (14337)

Showing 20 of 14337 trials
NCT07524530Phase 2Not Yet Recruiting

Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers

Role: lead

NCT05642195Phase 1Suspended

Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer

Role: lead

NCT05099003Phase 1Recruiting

A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)

Role: lead

NCT06096844Phase 3Recruiting

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

Role: lead

NCT06876142Phase 1Suspended

Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma

Role: lead

NCT04744116Early Phase 1Recruiting

Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease

Role: collaborator

NCT07328516Enrolling By Invitation

Natural History Study of Early Life Exposures in Agriculture (ELEA)

Role: lead

NCT04939090Phase 3Active Not Recruiting

Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients

Role: collaborator

NCT06337318Phase 3Recruiting

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

Role: lead

NCT06172296Phase 3Recruiting

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

Role: lead

NCT05896189Not ApplicableActive Not Recruiting

Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors

Role: collaborator

NCT01875601Phase 1Completed

NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors

Role: lead

NCT01169259Phase 3Active Not Recruiting

Vitamin D and Omega-3 Trial (VITAL)

Role: collaborator

NCT01272037Phase 3Active Not Recruiting

Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

Role: lead

NCT06790342Phase 3Not Yet Recruiting

Optimizing Treatment of Co-occurring Smoking and Unhealthy Alcohol Use Among PWH in Nairobi, Kenya

Role: collaborator

NCT05384756Phase 1Active Not Recruiting

TMLI and Alemtuzumab for Treatment of Sickle Cell Disease

Role: collaborator

NCT07509034Phase 1Not Yet Recruiting

Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease

Role: lead

NCT07572136Phase 1Not Yet Recruiting

Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Role: lead

NCT07686380Phase 2Not Yet Recruiting

IL-15 Superagonist With or Without Vaccine in Biochemically Recurrent Prostate Cancer After Previous Stereotactic Body Radiation Therapy

Role: lead

NCT05621291Not ApplicableRecruiting

A Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymph...

Role: lead